scholarly journals Radiographic evaluation of subcutaneously injected, water-soluble, iodinated contrast for lymphography

2018 ◽  
Author(s):  
Christopher E. Lee ◽  
Brad M. Matz ◽  
Robert C. Cole ◽  
Harry W. Boothe ◽  
D Michael Tillson
Keyword(s):  
Veterinary Medicine ◽  
Lymph Node ◽  
Median Time ◽  
Water Soluble ◽  
Popliteal Lymph Node ◽  
Radiographic Evaluation ◽  
Plantar Aspect ◽  
Iodinated Contrast ◽  
Specialized Equipment ◽  
Subcutaneous Tissues

AbstractSentinel lymph node (SLN) mapping is common in many types of human cancers, and is gaining utility in veterinary medicine. There are currently many different methods described in veterinary medicine for pre-operative SLN mapping, however, most of these are restricted to referral institutions due to cost and need for specialized equipment. The purpose of this prospective, pilot study was to evaluate the feasibility of radiographic evaluation of water-soluble, iodinated contrast (WIC) injected subcutaneously for lymphography in dogs. Eight dogs were injected with 1-2 milliliters of WIC into the subcutaneous tissues overlying the tarsus in 4 separate locations mimicking a circumferential, peri-tumoral injection. Radiographs were taken at select time points up to 50 minutes. Image sequences were evaluated by a single, board-certified radiologist. All 8 dogs had visible contrast-enhancing lymphatic channels. Median time to lymphatic enhancement was immediately post-injection. Seven dogs (88%) had 8 contrast enhancing lymph nodes (7 popliteal and 1 superficial inguinal). Median time to lymph node enhancement was 20 minutes. In this study, the plantar aspect of the pes drained to the superficial inguinal lymph node, and the dorsal aspect of the pes drained to the popliteal lymph node. Subcutaneously-injected WIC was readily identifiable in the lymphatic channels and draining lymph node(s). Subcutaneously injected WIC may offer a practical alternative to previously described pre-operative methods of SLN mapping. Additionally, one cannot assume that the popliteal lymph node alone, drains the distal pelvic limb.

Sentinel lymph node detection differs when comparing lymphoscintigraphy to lymphography using water soluble iodinated contrast medium and digital radiography in dogs

2020 ◽  
Vol 61 (6) ◽  
pp. 659-666
Author(s):  
Katelyn C. Hlusko ◽  
Robert Cole ◽  
David Michael Tillson ◽  
Harry W. Boothe ◽  
Greg Almond ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Contrast Medium ◽  
Digital Radiography ◽  
Water Soluble ◽  
Sentinel Lymph Node Detection ◽  
Iodinated Contrast Medium ◽  
Iodinated Contrast

Correction: In vivo Priming of T Cells with in vitro Pulsed Dendritic Cells: Popliteal Lymph Node Assay

BIO-PROTOCOL ◽  
2019 ◽  
Vol 9 (15) ◽  
Author(s):  
Songjie Cai ◽  
Masayuki Fujino ◽  
Lina Lu ◽  
Xiao-Kang Li
Keyword(s):  
T Cells ◽  
Dendritic Cells ◽  
Lymph Node ◽  
Popliteal Lymph Node ◽  
Popliteal Lymph Node Assay

The popliteal lymph node assay in mice to screen for the immune disregulating potential of chemicals — A preliminary study

1989 ◽  
Vol 11 (3) ◽  
pp. 293-300 ◽  
Author(s):  
M.E. Kammüller ◽  
C. Thomas ◽  
J.M. De Bakker ◽  
N. Bloksma ◽  
W. Seinen
Keyword(s):  
Lymph Node ◽  
Popliteal Lymph Node ◽  
Popliteal Lymph Node Assay ◽  
Preliminary Study

Intranodal CT Lymphangiography with Water-soluble Iodinated Contrast Medium for Imaging of the Central Lymphatic System

Radiology ◽  
2021 ◽  
Author(s):  
Suhag Patel ◽  
Saebeom Hur ◽  
Tamim Khaddash ◽  
Scott Simpson ◽  
Maxim Itkin
Keyword(s):  
Contrast Medium ◽  
Lymphatic System ◽  
Water Soluble ◽  
Iodinated Contrast Medium ◽  
Iodinated Contrast

scholarly journals Organic Nanoplatforms for Iodinated Contrast Media in CT Imaging

Molecules ◽  
2021 ◽  
Vol 26 (23) ◽  
pp. 7063
Author(s):  
Peng Zhang ◽  
Xinyu Ma ◽  
Ruiwei Guo ◽  
Zhanpeng Ye ◽  
Han Fu ◽  
...  
Keyword(s):  
Contrast Media ◽  
New Technologies ◽  
Drug Loading ◽  
Three Dimensional ◽  
Disease Diagnosis ◽  
Ct Imaging ◽  
Water Soluble ◽  
Iodinated Contrast Media ◽  
Iodinated Contrast ◽  
Anatomical Images

X-ray computed tomography (CT) imaging can produce three-dimensional and high-resolution anatomical images without invasion, which is extremely useful for disease diagnosis in the clinic. However, its applications are still severely limited by the intrinsic drawbacks of contrast media (mainly iodinated water-soluble molecules), such as rapid clearance, serious toxicity, inefficient targetability and poor sensitivity. Due to their high biocompatibility, flexibility in preparation and modification and simplicity for drug loading, organic nanoparticles (NPs), including liposomes, nanoemulsions, micelles, polymersomes, dendrimers, polymer conjugates and polymeric particles, have demonstrated tremendous potential for use in the efficient delivery of iodinated contrast media (ICMs). Herein, we comprehensively summarized the strategies and applications of organic NPs, especially polymer-based NPs, for the delivery of ICMs in CT imaging. We mainly focused on the use of polymeric nanoplatforms to prolong circulation time, reduce toxicity and enhance the targetability of ICMs. The emergence of some new technologies, such as theragnostic NPs and multimodal imaging and their clinical translations, are also discussed.

Tubular Nephrotoxicity of Water-soluble Iodinated Contrast Media

1980 ◽  
Vol 15 ◽  
pp. S54-S60 ◽  
Author(s):  
JEAN-FRANÇOIS MOREAU ◽  
DOMINIQUE DROZ ◽  
LAURE-HÉLÈNE NOEL ◽  
JACQUES LEIBOWITCH ◽  
PAUL JUNGERS ◽  
...  
Keyword(s):  
Contrast Media ◽  
Water Soluble ◽  
Iodinated Contrast Media ◽  
Iodinated Contrast

EFFECT OF X-IRRADIATION OF THE POPLITEAL LYMPH-NODE ON ITS OUTPUT OF LYMPHOCYTES AND IMMUNOLOGICAL RESPONSIVENESS

The Lancet ◽  
1964 ◽  
Vol 283 (7342) ◽  
pp. 1077-1080 ◽  
Author(s):  
J.G. Hall ◽  
Bede Morris
Keyword(s):  
Lymph Node ◽  
Popliteal Lymph Node ◽  
X Irradiation

UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castrate-sensitive prostate cancer.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 117-117
Author(s):  
Mary Mahler ◽  
Esmail Mutahar Al-Ezzi ◽  
Noa Shani Shrem ◽  
Eric Winquist ◽  
Christina M. Canil ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Lymph Node ◽  
Median Time ◽  
Median Number ◽  
Time To Progression ◽  
Chemohormonal Therapy ◽  
Radium 223 ◽  
Psa Response ◽  
Number Of Cycles

117 Background: Since docetaxel has been advanced to the metastatic castrate-sensitive prostate cancer (mCSPC) setting, there is a lack of evidence guiding its re-introduction upon castrate-resistant (CR) progression. We sought to identify clinical characteristics and outcomes of patients subjected to docetaxel rechallenge (DR) following prior docetaxel exposure in the mCSPC realm. Methods: Patients rechallenged with docetaxel following treatment in the mCSPC setting were identified from three academic centres in Ontario, Canada. Retrospective chart reviews were performed to identify clinical, treatment and outcome variables. Results: Of the 45 patients with DR initiated between 06/2015 and 07/2020, the median age was 65, 60% had a Gleason score of ≥8, and 64% had an ECOG of ≤1. 56% had bone only metastasis, 4% lymph node only metastasis, 29% bone and lymph node metastasis, and 11% had visceral metastasis. In the mCSPC setting, 98% of patients received 6 cycles of docetaxel with 13% requiring dose delays. Of 43 informative patients, all had a PSA response to chemohormonal therapy. 91% achieved at least a 50% PSA response (PSA50), of which 40% had a 50-89% PSA reduction and 51% had a ≥90% PSA reduction. 29% of patients obtained a PSA nadir of < 0.2 ng/mL. 16% had CR progression in < 6 months, 56% in 6-12 months, and 28% in > 12 months. DR was initiated after a median of 20.8 months (range 6.0-40.4) following the last dose of docetaxel for mCSPC, and was given as first line treatment for CR disease to 7%, second line to 51%, third line to 40%, and fourth line or beyond to 2% of patients. 69% of patients had received an androgen-receptor axis targeted therapy prior to DR, 18% radium 223, and 7% had received a trial drug. Notably, no patients had received cabazitaxel prior to DR. The median number of cycles of docetaxel received at rechallenge was 5 (range 1-11) with 18% of patients requiring treatment delays. 64% of patients stopped treatment due to progression, 16% due to side effects, 7% at the patient’s request, 7% due to completion of the planned number of cycles, and 6% due to death or other causes. Among 44 informative patients, 23% achieved at least a PSA50, with 18% having a 50-90% PSA reduction, and 5% having a ≥90% PSA reduction. The median time to progression (biochemical, radiographic, or death) was 2.3 months (95%CI 1.7-4.4) and the median overall survival was 11.0 months (95%CI 8.5-14.3). Conclusions: DR following exposure to docetaxel in the mCSPC setting resulted in a PSA50 in only around one quarter of patients. Both the median time to progression and overall survival were found to be short. With future investigations, we hope to identify clinical variables that will help predict which patients might benefit most from DR.

Sign in / Sign up

Export Citation Format

Share Document